GlassScriptPhysician profile
Michael Paltiel
NPI 1760525935
$13,350.46
in general payments reported to CMS, 2019-2025
33 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,322 · 2021: $2,705 · 2022: $1,837 · 2023: $1,898 · 2024: $2,026 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,870 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,870.30 |
| Education | $145.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,164.39 | 2019-2025 | |
| Pfizer INC. | $1,030.14 | 2019-2025 | |
| Lilly USA, LLC | $1,019.69 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $992.84 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $963.09 | 2019-2025 | Winlevi, Ilumya |
| Janssen Biotech, INC. | $920.00 | 2020-2025 | Tremfya, Remicade, Simponi Aria |
| Merz North America, INC. | $779.32 | 2021-2025 | |
| Amgen INC. | $535.56 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $532.50 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $471.01 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $447.61 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $435.78 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $352.51 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $342.02 | 2019-2025 | |
| Incyte Corporation | $341.41 | 2022-2025 | Opzelura, Opzelura |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $315.66 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $299.87 | 2019-2025 | Nemluvio, Dysport |
| Organon LLC | $205.18 | 2025 | Vtama |
| Celgene Corporation | $183.05 | 2019 | |
| Ucb, INC. | $163.77 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $152.76 | 2021-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $143.61 | 2024-2025 | Ycanth |
| Prugen, INC. Pharmaceuticals | $138.16 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $98.98 | 2019-2025 | Jublia |
| Dermira, INC. | $85.41 | 2020 | |
| Allergan, INC. | $57.85 | 2019-2022 | |
| Botanix Sb INC | $56.11 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $23.95 | 2025 | Spinosad, Natroba |
| Kyowa Kirin, INC. | $23.41 | 2024 | Poteligeo |
| Lnhc, INC | $23.27 | 2025 | Zelsuvmi |
| Epi Health, LLC | $20.82 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $17.26 | 2021 | |
| Mission Pharmacal Company | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Paltiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.